SELES, M., G. C. HUTTERER, J. FOSSELTEDER, Marek SVOBODA, M. RESEL, D. A. BARTH, R. PICHLER, T. BAUERNHOFER, R. E. ZIGEUNER, K. PUMMER, Ondřej SLABÝ, C. KLEC and M. PICHLER. Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer. Cancers. BASEL: MDPI, 2020, vol. 12, No 5, p. 1-17. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers12051200.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer
Authors SELES, M., G. C. HUTTERER, J. FOSSELTEDER, Marek SVOBODA (203 Czech Republic, belonging to the institution), M. RESEL, D. A. BARTH, R. PICHLER, T. BAUERNHOFER, R. E. ZIGEUNER, K. PUMMER, Ondřej SLABÝ (203 Czech Republic, belonging to the institution), C. KLEC (guarantor) and M. PICHLER.
Edition Cancers, BASEL, MDPI, 2020, 2072-6694.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.639
RIV identification code RIV/00216224:14740/20:00118647
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.3390/cancers12051200
UT WoS 000539246000141
Keywords in English long intergenic non-coding RNA; PANTR1; Linc01158; Linc-POU3F3; siRNA; renal cell cancer; clear-cell renal cell carcinoma; oncogene
Tags 14110513, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 26/4/2021 13:47.
Abstract
POU3F3 adjacent non-coding transcript 1 (PANTR1) is an oncogenic long non-coding RNA with significant influence on numerous cellular features in different types of cancer. No characterization of its role in renal cell carcinoma (RCC) is yet available. In this study, PANTR1 expression was confined to human brain and kidney tissue and was found significantly up-regulated in clear-cell renal cell carcinoma tissue (ccRCC) compared to non-cancerous kidney tissue in two independent cohorts (p < 0.001 for both cohorts). In uni- and multivariate Cox regression analysis, ccRCC patients with higher levels of PANTR1 showed significantly poorer disease-free survival in our own respective cohort (n = 175, hazard ratio: 4.3, 95% confidence interval: 1.45-12.75, p = 0.008) in accordance with significantly poorer overall survival in a large The Cancer Genome Atlas database (TCGA) cohort (n = 530, hazard ratio: 2.19, 95% confidence interval: 1.59-3.03, p 0.001). To study the underlying cellular mechanisms mediated by varying levels of PANTR1 in kidney cancer cells, we applied siRNA-mediated knock-down experiments in three independent ccRCC cell lines (RCC-FG, RCC-MF, 769-P). A decrease in PANTR1 levels led to significantly reduced cellular growth through activation of apoptosis in all tested cell lines. Moreover, as angiogenesis is a critical driver in ccRCC pathogenesis, we identified that PANTR1 expression is critical for in vitro tube formation and endothelial cell migration (p < 0.05). On the molecular level, knock-down of PANTR1 led to a decrease in Vascular Endothelial growth factor A (VEGF-A) and cell adhesion molecule laminin subunit gamma-2 (LAMC2) expression, corroborated by a positive correlation in RCC tissue (for VEGF-A R = 0.19, p < 0.0001, for LAMC2 R = 0.13, p = 0.0028). In conclusion, this study provides first evidence that PANTR1 has a relevant role in human RCC by influencing apoptosis and angiogenesis.
Links
NV18-03-00554, research and development projectName: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii
Investor: Ministry of Health of the CR
824036, interní kód MUName: Excellence in research and development of non-coding RNA DIAGnostics in ONcology (Acronym: RNADIAGON)
Investor: European Union, MSCA Marie Skłodowska-Curie Actions (Excellent Science)
90125, large research infrastructuresName: BBMRI-CZ III
PrintDisplayed: 17/7/2024 07:30